Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

Publication | Closed Access

DOI

Citations

References

2017

Year

Laura Ciaffi, Sinata Koulla‐Shiro, Adrien Sawadogo, Cheik Tidiane Ndour, Sabrina Eymard‐Duvernay, Pretty Rosereine Mbouyap, Liliane Ayangma, Jacques Zoungrana, Ndèye Fatou Ngom Gueye, Mohamadou Diallo,

The Lancet HIV

Lamivudine Dual TherapySuperiority TrialProtease InhibitorTreatment And PreventionGlobal HealthAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyPharmacotherapyAntiviral DrugHivMedicine